Results 41 to 50 of about 3,667 (197)
INNOVATIONS in Pharmacy, 2021 Purpose: This case report details the influence of media on patients and the responsibility of health care providers to educate their patients on proper use of medications, and to be aware of potential misadventures based on messages in popular media ...
Shaylee Anderson +2 more
doaj +1 more source
An atypical presentation of malaria in a 19-year-old woman
IDCases, 2022 We describe an atypical presentation of malaria in a 19-year-old female who emigrated from Nigeria to the United States one year prior to presentation. Her primary complaint was fever and occipital headache radiating down to the neck.
Radhika Malhotra +3 more
doaj +1 more source
Progression of Malaria in the Human Body, Its Effects on the Liver and Its Various Aspects
Advanced Gut &Microbiome Research, Volume 2026, Issue 1, 2026.Malaria, an infectious disease caused by Plasmodium parasites, is a significant global health issue, particularly in tropical and subtropical regions. Understanding the development of malaria in the human body and its effects on vital organs like the liver is crucial for effective control and prevention.
Avishek Mandal +7 more
wiley +1 more source
Unveiling Antimalarial Drug Resistance: The Role of CRISPR‐Cas Technologies in Malaria Research
Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.Background Malaria, caused by Plasmodium parasites, remains a global health burden, with drug resistance threatening control efforts. CRISPR‐Cas technologies, particularly CRISPR‐Cas9, have transformed malaria research by enabling precise genetic manipulations to study antimalarial resistance mechanisms, develop novel therapeutics and enhance ...
Reuben Samson Dangana +3 more
wiley +1 more source
A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria. [PDF]
PLoS ONE, 2012 The predominance of chloroquine-susceptible falciparum malaria in Malawi more than a decade after chloroquine's withdrawal permits contemplation of re-introducing chloroquine for targeted uses.
Miriam K Laufer +8 more
doaj +1 more source
Cyclization-blocked proguanil as a strategy to improve the antimalarial activity of atovaquone
, 2019 Atovaquone-proguanil (Malarone®) is used for malaria prophylaxis and treatment. While the cytochrome bc1-inhibitor atovaquone has potent activity, proguanil’s action is attributed to its cyclization-metabolite, cycloguanil.
Antonova-Koch, Yevgeniya +31 more
core +1 more source
Journal of Parasitology Research, Volume 2026, Issue 1, 2026.Background By the mid‐20th century, Europe eradicated endemic malaria. However, the significance of imported infections in nonendemic regions is growing. These cases often constitute the majority, can sustain transmission, trigger relapses, and increase mortality in these areas. Methods We conducted a retrospective, single‐center study of patients with
Patricia Mester +10 more
wiley +1 more source
Sequence analysis of
Malaria Journal, 2007 Background The antimalarial drug atovaquone specifically targets Plasmodium falciparum cytochrome b (Pfcytb), a mitochondrial gene with uniparental inheritance.
Henry Marie-Claire +11 more
doaj +1 more source
Atovaquone-proguanil for treating uncomplicated malaria [PDF]
Cochrane Database of Systematic Reviews, 2003 Many conventional treatments for uncomplicated malaria are failing because malaria parasites develop resistance to them. One way to combat this resistance is to treat people with a combination of drugs, such as atovaquone-proguanil.To compare atovaquone-proguanil with other antimalarial drugs (alone or in combination) for treating children and adults ...
A, Osei-Akoto +2 more
openaire +2 more sources
A Novel Inhibitor against the Bromodomain Protein 1 of the Malaria Pathogen Plasmodium Falciparum
ChemMedChem, Volume 20, Issue 11, June 2, 2025.This article presents the development of a first‐in‐class inhibitor targeting the bromodomain protein PfBDP1 in Plasmodium falciparum, the deadliest variant of the malaria‐causing Plasmodium parasites. Through structure‐based drug design, the inhibitor interactions were characterized via X‐ray crystallography and isothermal titration calorimetry ...
Marius Amann +10 more
wiley +1 more source